Medicalgorithmics SA

Medicalgorithmics SA has a capital structure characterized by a debt-to-equity ratio of 0.1, indicating a relatively low reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 2.49, suggesting it can cover its short-term liabilities with its current assets. However, the company has no cash and equivalents and a negative net cash position after subtracting total debt, which may pose liquidity challenges. In terms of profitability, Medicalgorithmics SA reported a net loss of 16,081,000 PLN and an operating loss of 16,538,000 PLN in the latest financial period. The company's return on equity (ROE) is -20.84%, and its return on assets (ROA) is -15.2%, both significantly below the industry norms for profitable operations. These metrics suggest the company is not currently generating returns that meet the expectations of its equity and asset base. The company's revenue is primarily concentrated in its core product, PocketECG, and related services in information technology and biotechnology. There is no detailed breakdown of revenue by geographic region or segment in the provided data, but the company operates through subsidiaries in the US and is based in Poland, indicating some geographic diversification. Looking at the growth trajectory, the company has not provided specific numeric deltas for the current or next fiscal year. However, the operating cash flow is negative at -13,079,000 PLN, and the free cash flow is also negative at -12,583,000 PLN, indicating that the company is not generating positive cash from operations. This suggests that the company may need to rely on external financing to fund its operations and growth initiatives. The risk assessment for Medicalgorithmics SA highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. There is no indication of dilution potential in the basic shares outstanding, as the diluted shares are the same as the basic shares. The company has not made any recent public filings or transcripts that would indicate significant changes in its business or financial condition. Recent events and filings do not show any major developments for Medicalgorithmics SA. The company's financial performance and operational cash flows suggest ongoing challenges in achieving profitability and positive cash generation. Analysts have provided a mean price target of 44.70 PLN, with a mean recommendation of 1.50, indicating a generally positive outlook despite the company's current financial position.